The molecular diagnostics market is one of the most rapidly growing segments of the in vitro diagnostics industry. Molecular diagnostics refers to a technique used to detect and identify the presence of genetic material or proteins associated with a specific health condition or disease. The United States is the key market for molecular diagnostics due to the availability of government funds, rising incidence of chronic diseases, the availability of different types of tests, and high awareness of pharmacogenomics/personalized medicine. Moreover, major companies have easy access to United States which makes the United States the largest and most significant market for suppliers.

United States Molecular Diagnostics Market and Test Volume - Application Segment Analysis: In United States molecular diagnostic market, infectious disease controls the maximum share of the market. Molecular oncology tests have emerged as a significant rapidly growing market segment. Increased public awareness of the relationship between genetics and personal health has increased the demand for molecular genetic testing. The genetic testing is the third leading segment of the molecular diagnostics market followed by the blood screening test market. Molecular diagnostics is also gaining popularity as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas.

United States is the major food safety testing market. The food pathogen test volume accounts for the maximum share of the molecular diagnostics volume. The infectious disease at the second spot in molecular diagnostics application test volume with nearly XX% volume share in 2014. The oncology testing stands at the third spot in molecular diagnostics test volume followed by the blood screening test. Genetic testing and HLA tests are also gaining popularity in the molecular diagnostics landscape.

United States Molecular Diagnostics Market - Company Analysis: In the United States molecular diagnostics market, Hologic Inc. captures the maximum share of the market. Myriad Genetics holds the second position in the United States molecular diagnostics market being followed by Roche. In 2014, Molecular Diagnostics accounted for 50% of Qiagen total sales. In 2015, Cepheid is anticipated to extend the market segment reach with entry into the CLIA-waived testing market in the US.

iGATE RESEARCH report titled “United States - Molecular Diagnostics Market, Test Volume and Company Analysis to 2020” is a 130 page report with 87 Figures. This report studies in detail the United States Molecular Diagnostics Market and Test Volume, United States Molecular Diagnostics Company Sales Analysis along with the Driving Factors and Challenges for the United States Molecular Diagnostics Market.

The United States Molecular Diagnostics Market has been analysed from 4 View Points:

1) United States - Molecular Diagnostics Market and Forecast
2) United States Molecular Diagnostics Market - Application Segment Analysis
3) United States Molecular Diagnostics Market - Application Segment Test Volume Analysis
4) United States Molecular Diagnostics Market - Company Sales Analysis

United States Molecular Diagnostics Market and Test Volume - Application Segment Analysis (2010 - 2020)

1. Oncology Testing
a) Breast Cancer
b) Colorectal Cancer
c) Prostate Cancer
d) Others

2. Infectious Diseases
a) Virology Testing
b) HPV Testing
c) HAI Testing
d) Critical Care Testing

3. Genetic Testing
4. Blood Screening
5. Food Pathogen Testing
6. Tissue Typing (HLA Testing)

United States Molecular Diagnostics - Company Sales Analysis (2010 - 2020)

1. Roche
2. Abbott
3. Myriad Genetics
4. BioMerieux
5. Qiagen
6. Hologic Inc.
7. Becton Dickinson
8. Siemens
9. Cepheid
10. Others

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

1. Executive Summary

2. United States - Molecular Diagnostics Market, Test Volume and Forecast (2010 - 2020)

2.1 United States - Molecular Diagnostics Market and Forecast
2.2 United States - Molecular Diagnostics Test Volume and Forecast

3. United States - Molecular Diagnostics Market and Volume Share (2010 - 2020)

3.1 United States - Application Wise Molecular Diagnostics Market Share and Forecast
3.2 United States - Company Wise Molecular Diagnostics Market Share and Forecast
3.3 United States Molecular Diagnostics Test Volume Share and Forecast - Application Wise

4. United States Molecular Diagnostics Market and Forecast - Application Wise

4.1 Oncology Testing Market (2004 - 2020)

4.1.1 Breast Cancer Testing Market (2004 - 2020)
4.1.2 Colorectal Cancer Testing Market (2004 - 2020)
4.1.3 Prostate Cancer Testing Market (2004 - 2020)
4.1.4 Other Cancer Testing Market (2004 - 2020)

4.2 Infectious Disease Testing Market (2010 - 2020)

4.2.1 Virology Testing Market (2007 - 2020)
4.2.2 HPV Testing Market (2004 - 2020)
4.2.3 HAI Testing Market (2010 - 2020)
4.2.4 Critical Care Testing Market (2010 - 2020)

4.3 Genetic Testing Market (2010 - 2020)
4.4 Blood Screening Market (2006 - 2020)
4.5 Food Pathogen Testing Market (2010 - 2020)
4.6 Tissue Typing (HLA) Testing Market (2008 - 2020)

5. United States Molecular Diagnostics Test Volume - Application Wise

5.1 Oncology Test Volume (2004 - 2020)

5.1.1 Breast Cancer Test Volume (2004 - 2020)
5.1.2 Colorectal Cancer Test Volume (2004 - 2020)
5.1.3 Prostate Cancer Test Volume (2004 - 2020)
5.1.4 Other Cancer Test Volume (2004 - 2020)

5.2 Infectious Disease Test Volume (2010 - 2020)

5.2.1 Virology Test Volume (2007 - 2020)
5.2.2 HPV Test Volume (2004 - 2020)
5.2.3 HAI Test Volume (2010 - 2020)
5.2.4 Critical Care Test Volume (2010 - 2020)

5.3 Genetic Testing Test Volume and Forecast (2010 - 2020)
5.4 Blood Screening Test Volume and Forecast (2006 - 2020)
5.5 Food Pathogen Test Volume and Forecast (2010 - 2020)
5.6 HLA Test Volume and Forecast (2008 - 2020)

6. United States Molecular Diagnostics Market - Company Wise

6.1 Roche - United States Molecular Diagnostic Sales and Forecast
6.2 Abbott Laboratories - United States Molecular Diagnostic Sales and Forecast
6.3 Myriad Genetics - United States Molecular Diagnostic Sales and Forecast
6.4 Biomerieux - United States Molecular Diagnostic Sales and Forecast
6.5 Qiagen - United States Molecular Diagnostic Sales and Forecast
6.6 Hologic Inc. (Acquired Gen-Probe) - United States Molecular Diagnostic Sales and Forecast
6.7 Becton Dickinson - United States Molecular Diagnostic Sales and Forecast
6.8 Siemens - United States Molecular Diagnostic Sales and Forecast
6.9 Cepheid - United States Molecular Diagnostic Sales and Forecast
6.10 Others - United States Molecular Diagnostic Sales and Forecast

7. United States Molecular Diagnostics Market - Driving Factors

7.1 Increasing Automation to Drive the Molecular Diagnostics Market
7.2 Investment in Genomics and Proteomics Research
7.3 Personalized Medicine Fuels Molecular Diagnostics

8. United States Molecular Diagnostics Market - Challenges

8.1 Regulatory Issues
8.2 Reimbursement Capabilities
8.3 Quality Checkpoints, Awareness and Acceptance